Reuters logo
BRIEF-Catalyst Biosciences announces achievement of stable normal factor IX blood levels in a preclinical subcutaneous dosing model
June 26, 2017 / 12:15 PM / 3 months ago

BRIEF-Catalyst Biosciences announces achievement of stable normal factor IX blood levels in a preclinical subcutaneous dosing model

June 26 (Reuters) - Catalyst Biosciences Inc

* Catalyst Biosciences announces achievement of stable normal factor IX blood levels in a preclinical subcutaneous dosing model Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below